Abstract 87P
Background
Systemic anticancer therapies have advanced beyond cytotoxic agents; checkpoint inhibitors have revolutionised cancer therapeutics and are now in routine use across multiple disease sites. The mechanism of action places patients at risk of immune-related (IR) side effects including IR colitis (IRC). The management of IRC is described in guidelines, however, in the UK access to some recommended therapies, particularly for steroid refractory IRC, including vedolizumab, remains unclear. We aimed to evaluate vedolizumab access and usage for IRC in UK hospitals.
Methods
We surveyed the use of vedolizumab across UK hospitals; the questionnaire was available between June and July 2024. Questions were developed to identify current practice focusing on preferred treatment guidelines, access to vedolizumab and treatment pathways. An electronic Microsoft Forms questionnaire was disseminated across 2 platforms; via email to all British Oncology Pharmacy Association (BOPA) members, and via presentation and QR code to Immuno-Oncology Clinical Network (IOCN) members for real-time completion. After removing duplicate hospital entries, data was analysed and grouped into themes.
Results
A total of 74 responses were received: 46% by pharmacists (n=34) and 31% by doctors (n=23). Duplicate hospital sites were subsequently combined, and the remaining 46 responses analysed. 65% hospitals (n=30) use ESMO or Clatterbridge cancer centre IRC guidelines. 93% hospitals (n=43) use infliximab 1st line in steroid refractory IRC. 57% hospitals (n=26) have used vedolizumab for 2nd line use, whilst 11% (n=5) hospitals have used it at any line of their IRC treatment pathway. 22% (n=10) hospitals have never used vedolizumab of which funding, experience, willingness to prescribe and lack of place in existing treatment pathways; are contributing factors.
Conclusions
Vedolizumab is used as a 2nd line option for IRC in over half of responding hospitals, however, there is disparity in its usage. The barriers to implementation appear to be primarily driven by funding, willingness to prescribe and experience. Real-world studies on the efficacy of Vedolizumab are warranted to further establish its place in the IRC pathway to recommend as a treatment option.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract